Prednisolone inclusion in a first-line multidrug cytostatic protocol for the treatment of canine lymphoma does not affect therapy results

Veterinary Journal

Volumn 197, Issue 3, 2013, Pages 656-661

  Zandvliet, M ^a   Rutteman, G R ^a   Teske, E ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Chemotherapy; Dog; Glucocorticoids; Lymphoma; Non Hodgkin

Indexed keywords

ASPARAGINASE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; MITOXANTRONE; PREDNISOLONE; VINCRISTINE;

ADVERSE DRUG REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOG DISEASE; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; HEMORRHAGIC CYSTITIS; IMMUNOPHENOTYPING; LYMPHOMA; MALE; NONHUMAN; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; T CELL LYMPHOMA;

CANIS FAMILIARIS;

CHEMOTHERAPY; DOG; GLUCOCORTICOIDS; LYMPHOMA; NON-HODGKIN;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOG DISEASES; DOGS; FEMALE; LYMPHOMA; MALE; PREDNISOLONE; TREATMENT OUTCOME;

EID: 84884989290     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2013.04.022     Document Type: Article

References (37)

1. Allenspach K., Bergman P.J., Sauter S., Grone A., Doherr M.G., Gaschen F. P-glycoprotein expression in lamina propria lymphocytes of duodenal biopsy samples in dogs with chronic idiopathic enteropathies. Journal of Comparative Pathology 2006, 134:1-7.
2. Ammersbach M.A., Kruth S.A., Sears W., Bienzle D. The effect of glucocorticoids on canine lymphocyte marker expression and apoptosis. Journal of Veterinary Internal Medicine 2006, 20:1166-1171.
3. Aulbach A.D., Swenson C.L., Kiupel M. Optimized processing of fine-needle lymph node biopsies for automated immunostaining. Journal of Veterinary Diagnostic Investigation 2010, 22:383-388.
4. Bergman P.J., Ogilvie G.K., Powers B.E. Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: Sequential analysis and predictive ability in dogs with lymphoma. Journal of Veterinary Internal Medicine 1996, 10:354-359.
5. Cotter S.M., Goldstein M.A. Treatment of lymphoma and leukemia with cyclophosphamide, vincristine, and prednisone. Journal of the American Animal Hospital Association 1983, 19:159-165.
6. Dobson J.M., Samuel S., Milstein H., Rogers K., Wood J.L. Canine neoplasia in the UK: Estimates of incidence rates from a population of insured dogs. The Journal of Small Animal Practice 2002, 43:240-246.
7. Efferth T., Konkimalla V.B., Wang Y.F., Sauerbrey A., Meinhardt S., Zintl F., Mattern J., Volm M. Prediction of broad spectrum resistance of tumors towards anticancer drugs. Clinical Cancer Research 2008, 14:2405-2412.
8. Fisher R.I., Gaynor E.R., Dahlberg S., Oken M.M., Grogan T.M., Mize E.M., Glick J.H., Coltman C.A., Miller T.P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. The New England Journal of Medicine 1993, 328:1002-1006.
9. Flory A.B., Rassnick K.M., Erb H.N., Garrett L.D., Northrup N.C., Selting K.A., Phillips B.S., Locke J.E., Chretin J.D. Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007). Journal of the American Veterinary Medical Association 2011, 238:501-506.
10. Garrett L.D., Thamm D.H., Chun R., Dudley R., Vail D.M. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. Journal Veterinary Internal Medicine 2002, 16:704-709.
11. Gavazza A., Lubas G., Valori E., Gugliucci B. Retrospective survey of malignant lymphoma cases in the dog: Clinical, therapeutical and prognostic features. Veterinary Research Communications 2008, 32:S291-293.
12. Gillet J.P., Gottesman M.M. Mechanisms of multidrug resistance in cancer. Methods in Molecular Biology 2010, 596:47-76.
13. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nature Reviews Cancer 2002, 2:48-58.
14. Jeffers J.G., Shanley K.J., Schick R.O. Diabetes mellitus induced in a dog after administration of corticosteroids and methylprednisolone pulse therapy. Journal of the American Veterinary Medical Association 1991, 199:77-80.
15. Kfir-Erenfeld S., Sionov R.V., Spokoini R., Cohen O., Yefenof E. Protein kinase networks regulating glucocorticoid-induced apoptosis of hematopoietic cancer cells: Fundamental aspects and practical considerations. Leukemia and Lymphoma 2010, 51:1968-2005.
16. Lee J.J., Hughes C.S., Fine R.L., Page R.L. P-glycoprotein expression in canine lymphoma: A relevant, intermediate model of multidrug resistance. Cancer 1996, 77:1892-1898.
17. Manceau S., Giraud C., Decleves X., Batteux F., Chereau C., Chouzenoux S., Scherrmann J.M., Weill B., Perrot J.Y., Treluyer J.M. Expression and induction by dexamethasone of ABC transporters and nuclear receptors in a human T-lymphocyte cell line. Journal of Chemotherapy 2012, 24:48-55.
18. Marconato L., Stefanello D., Valenti P., Bonfanti U., Comazzi S., Roccabianca P., Caniatti M., Romanelli G., Massari F., Zini E. Predictors of long-term survival in dogs with high-grade multicentric lymphoma. Journal of the American Veterinary Medical Association 2011, 238:480-485.
19. Moore A.S., Cotter S.M., Rand W.M., Wood C.A., Williams L.E., London C.A., Frimberger A.E., L'Heureux D.A. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma. Journal of Veterinary Internal Medicine 2001, 15:348-354.
20. Myers N.C., Moore A.S., Rand W.M., Gliatto J., Cotter S.M. Evaluation of a multidrug chemotherapy protocol (ACOPA II) in dogs with lymphoma. Journal of Veterinary Internal Medicine 1997, 11:333-339.
21. Owen L.N. TNM Classification of Tumours in Domestic Animals 1980, World Health Organization.
22. Perry J.A., Thamm D.H., Eickhoff J., Avery A.C., Dow S.W. Increased monocyte chemotactic protein-1 concentration and monocyte count independently associate with a poor prognosis in dogs with lymphoma. Veterinary and Comparative Oncology 2011, 9:55-64.
23. Piek C.J., Rutteman G.R., Teske E. Evaluation of the results of an L-asparaginase-based continuous chemotherapy protocol versus a short doxorubicin-based induction chemotherapy protocol in dogs with malignant lymphoma. Veterinary Quarterly 1999, 21:44-49.
24. Ponce F., Marchal T., Magnol J.P., Turinelli V., Ledieu D., Bonnefont C., Pastor M., Delignette M.L., Fournel-Fleury C. A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology. Veterinary Pathology 2010, 47:414-433.
25. Price G.S., Page R.L., Fischer B.M., Levine J.F., Gerig T.M. Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma. Journal of Veterinary Internal Medicine 1991, 5:259-262.
26. Rewerts J.M., Grooters A.M., Payne J.T., Kornegay J.N. Atraumatic rupture of the gastrocnemius muscle after corticosteroid administration in a dog. Journal of the American Veterinary Medical Association 1997, 210:655-657.
27. Squire R.A., Bush M., Melby E.C., Neeley L.M., Yarbrough B. Clinical and pathologic study of canine lymphoma: Clinical staging, cell classification, and therapy. Journal of the National Cancer Institute 1973, 51:565-574.
28. Steingold S.F., Sharp N.J., McGahan M.C., Hughes C.S., Dunn S.E., Page R.L. Characterization of canine MDR1 mRNA: Its abundance in drug resistant cell lines and in vivo. Anticancer Research 1998, 18:393-400.
29. Teske E. Canine malignant lymphoma: A review and comparison with human non-Hodgkin's lymphoma. Veterinary Quarterly 1994, 16:209-219.
30. Teske E., van Heerde P., Rutteman G.R., Kurzman I.D., Moore P.F., MacEwen E.G. Prognostic factors for treatment of malignant lymphoma in dogs. Journal of the American Veterinary Medical Association 1994, 205:1722-1728.
31. Teske E., Wisman P., Moore P.F., van Heerde P. Histologic classification and immunophenotyping of canine non-Hodgkin's lymphomas: Unexpected high frequency of T cell lymphomas with B cell morphology. Experimental Hematology 1994, 22:1179-1187.
32. Torres S.M., Diaz S.F., Nogueira S.A., Jessen C., Polzin D.J., Gilbert S.M., Horne K.L. Frequency of urinary tract infection among dogs with pruritic disorders receiving long-term glucocorticoid treatment. Journal of the American Veterinary Medical Association 2005, 227:239-243.
33. Vail D.M., Michels G.M., Khanna C., Selting K.A., London C.A., Veterinary Cooperative Oncology Group Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0) - A Veterinary Cooperative Oncology Group (VCOG) consensus document. Veterinary and Comparative Oncology 2010, 8:28-37.
34. Vail D.M., Pinkerton M.E., Young K.M. Canine lymphoma and lymphoid leukemias. Withrow and MacEwen's Small Animal Clinical Oncology 2013, 608-637. W.B. Saunders, Saint Louis. S.J. Withrow, D.M. Vail, R.L. Page (Eds.).
35. Veterinary Co-operative Oncology Group (VCOG) Veterinary Co-operative Oncology Group - Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Veterinary and Comparative Oncology 2004, 2:195-213.
36. Vezzali E., Parodi A.L., Marcato P.S., Bettini G. Histopathologic classification of 171 cases of canine and feline non-Hodgkin lymphoma according to the WHO. Veterinary and Comparative Oncology 2010, 8:38-49.
37. Wasilewska A.M., Zoch-Zwierz W.M., Pietruczuk M. Expression of P-glycoprotein in lymphocytes of children with nephrotic syndrome treated with glucocorticoids. European Journal of Pediatrics 2006, 165:839-844.